Biography for Damian Garde
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
Covidien is gearing up to launch its Kangaroo feeding tube in the U.S. after picking up FDA clearance for the device, which is outfitted with a camera that provides real-time images to physicians.
Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
Thanks to an FDA ruling, a fleet of Medtronic pacemakers and defibrillators are now cleared for use in patients with less severe heart failure.
SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans.
Abbott Laboratories has wrapped up enrollment in a 2,000-patient trial designed to win FDA approval for Absorb, its dissolvable vascular scaffold, setting sights on the world's largest market after charting success abroad.
Venture capital outfit Split Rock Partners is planning to abandon the medical device industry, Forbes reports, looking to ditch healthcare investments and refocus on Internet services.
Medtronic is headed to the European market with what it says is the first implantable defibrillator cleared for full-body MRI scans, following a widespread trend toward imaging-safe implants.
Boston Scientific has launched its much-hyped S-ICD in Asia, notching the first implant of the under-the-skin system in Hong Kong as it looks to expand the market for the device.
A combination of physical therapy and treatment with Medtronic's spinal-cord-stimulating devices helped three men with paraplegia move their extremities and briefly stand up on their own, The Wall Street Journal reports, regaining voluntary movement years after their injuries.